We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Pharmaceutical Research and Manufacturers of America (PhRMA) is calling on the World Trade Organization (WTO) to reject a proposal that would temporarily revoke patents for COVID-19 vaccines and treatments, ahead of a WTO meeting on intellectual property scheduled for tomorrow. Read More
St. Petersburg, Russia-based Pharmsynthez has reportedly begun manufacturing a generic version of Gilead Sciences’ COVID-19 antiviral treatment Veklury (remdesivir) without the U.S. company’s permission. Read More
Peer-reviewed interim results from the Gamaleya Research Institute’s phase 3 vaccine trial showed that its Sputnik V vaccine was safe and nearly 92 percent effective against symptomatic coronavirus, encouraging results that line up with previous data released by Moscow researchers. Read More
The Pfizer/BioNTech vaccine may not protect against a key mutation found on the coronavirus variant identified in South Africa, B.1.351, new UK research suggests. Read More
The AstraZeneca/Oxford University COVID-19 vaccine offers sustained protection of 76 percent effectiveness for three months following an initial dose, Oxford researchers reported in early results from multiple trials in the UK, Brazil and South Africa. Read More
As the U.S. impatiently awaits delivery of many more millions of doses of the two currently authorized COVID-19 vaccines, Pfizer/BioNTech and Moderna said they are confident that they can fully deliver what’s been ordered to date in the next few months — and that they have shipped around 59.4 million doses so far. Read More
The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has begun a rolling review of Regeneron’s REGN-COV2 antibody combination (casirivimab/imdevimab) for treating and preventing COVID-19. Read More
AstraZeneca (AZ) has promised to deliver an additional 9 million doses of its vaccine to EU member states during the first quarter of this year, bringing its total delivery for the period up to 40 million — but still only half of the initial 80 million-dose commitment in its contract with the bloc. Read More
A “streamlined” process for authorizing COVID-19 vaccines modified to address significant new coronavirus strains is in the works to enable the FDA to quickly react to significant viral mutations, said Center for Biologics Evaluation and Research (CBER) Director Peter Marks. Read More
French vaccine company Valneva said it has begun production of its investigational COVID-19 vaccine, which is now in a phase 1/2 clinical trial in the UK. Read More